Overview
- In a 36‑week interim analysis of 199 patients, povetacicept cut proteinuria by 52% versus 4.3% with placebo.
- Secondary measures improved, including a 79.3% drop in pathogenic antibody levels and resolution of hematuria in more than 85% of treated patients, with reported good tolerability.
- Vertex said it will complete its IgAN application by month‑end and submit it to the FDA using a priority review voucher that can shorten review from about 10 months to six.
- Shares rose roughly 8% to 10% as analysts raised targets and ratings, with Jefferies initiating at buy with a $580 target and Cantor and Evercore at $590 and $530.
- The two‑year RAINIER study continues toward its 605‑patient final outcomes as Vertex builds a renal franchise from its 2024 Alpine Immune Sciences acquisition.